212 related articles for article (PubMed ID: 37398358)
1. Dynamical modelling of proliferative-invasive plasticity and IFNγ signaling in melanoma reveals mechanisms of PD-L1 expression heterogeneity.
Subhadarshini S; Sahoo S; Debnath S; Somarelli JA; Jolly MK
bioRxiv; 2023 Jun; ():. PubMed ID: 37398358
[TBL] [Abstract][Full Text] [Related]
2. Dynamical modeling of proliferative-invasive plasticity and IFNγ signaling in melanoma reveals mechanisms of PD-L1 expression heterogeneity.
Subhadarshini S; Sahoo S; Debnath S; Somarelli JA; Jolly MK
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37678920
[TBL] [Abstract][Full Text] [Related]
3. SOX10 Inhibits T Cell Recognition by Inducing Expression of the Immune Checkpoint Molecule PD-L1 in A375 Melanoma Cells.
Sasaki K; Hirohashi Y; Murata K; Minowa T; Nakatsugawa M; Murai A; Mizue Y; Kubo T; Kanaseki T; Tsukahara T; Iwabuchi S; Hashimoto S; Uhara H; Ishida-Yamamoto A; Torigoe T
Anticancer Res; 2023 Apr; 43(4):1477-1484. PubMed ID: 36974807
[TBL] [Abstract][Full Text] [Related]
4. Systems-level network modeling deciphers the master regulators of phenotypic plasticity and heterogeneity in melanoma.
Pillai M; Jolly MK
iScience; 2021 Oct; 24(10):103111. PubMed ID: 34622164
[TBL] [Abstract][Full Text] [Related]
5. COX-2 expression positively correlates with PD-L1 expression in human melanoma cells.
Botti G; Fratangelo F; Cerrone M; Liguori G; Cantile M; Anniciello AM; Scala S; D'Alterio C; Trimarco C; Ianaro A; Cirino G; Caracò C; Colombino M; Palmieri G; Pepe S; Ascierto PA; Sabbatino F; Scognamiglio G
J Transl Med; 2017 Feb; 15(1):46. PubMed ID: 28231855
[TBL] [Abstract][Full Text] [Related]
6. Functional Downregulation of PD-L1 and PD-L2 by CpG and non-CpG Oligonucleotides in Melanoma Cells.
Kleemann J; Steinhorst K; König V; Zöller N; Cinatl J; Özistanbullu D; Kaufmann R; Meissner M; Kippenberger S
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230620
[TBL] [Abstract][Full Text] [Related]
7. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
8. Bidirectional crosstalk between epithelial-mesenchymal plasticity and IFN
Burger GA; Nesenberend DN; Lems CM; Hille SC; Beltman JB
R Soc Open Sci; 2022 Nov; 9(11):220186. PubMed ID: 36397970
[TBL] [Abstract][Full Text] [Related]
9. Emergent dynamics of underlying regulatory network links EMT and androgen receptor-dependent resistance in prostate cancer.
Jindal R; Nanda A; Pillai M; Ware KE; Singh D; Sehgal M; Armstrong AJ; Somarelli JA; Jolly MK
Comput Struct Biotechnol J; 2023; 21():1498-1509. PubMed ID: 36851919
[TBL] [Abstract][Full Text] [Related]
10. IFNγ/PD-L1 Signaling Improves the Responsiveness of Anti-PD-1 Therapy in Colorectal Cancer: An in vitro Study.
Yuan W; Deng D; Li H; Hu X; Shang X; Hou X; Jiang H; He H
Onco Targets Ther; 2021; 14():3051-3062. PubMed ID: 33994797
[TBL] [Abstract][Full Text] [Related]
11. Interferon Signaling Is Frequently Downregulated in Melanoma.
Alavi S; Stewart AJ; Kefford RF; Lim SY; Shklovskaya E; Rizos H
Front Immunol; 2018; 9():1414. PubMed ID: 29977240
[TBL] [Abstract][Full Text] [Related]
12. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
[TBL] [Abstract][Full Text] [Related]
13. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS
Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323
[TBL] [Abstract][Full Text] [Related]
14. Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma.
Yeon M; Kim Y; Jung HS; Jeoung D
Front Cell Dev Biol; 2020; 8():486. PubMed ID: 32626712
[TBL] [Abstract][Full Text] [Related]
15. The Prognostic and Predictive Value of Human Gastrointestinal Microbiome and Exosomal mRNA Expression of PD-L1 and IFNγ for Immune Checkpoint Inhibitors Response in Metastatic Melanoma Patients: PROTOCOL TRIAL.
Erman A; Ignjatović M; Leskovšek K; Miceska S; Lampreht Tratar U; Bošnjak M; Kloboves Prevodnik V; Čemažar M; Kandolf Sekulovič L; Avguštin G; Ocvirk J; Mesti T
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509655
[TBL] [Abstract][Full Text] [Related]
16. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
17. A secondary role for hypoxia and HIF1 in the regulation of (IFNγ-induced) PD-L1 expression in melanoma.
van Duijn A; Willemsen KJ; van Uden NOP; Hoyng L; Erades S; Koster J; Luiten RM; Bakker WJ
Cancer Immunol Immunother; 2022 Mar; 71(3):529-540. PubMed ID: 34268602
[TBL] [Abstract][Full Text] [Related]
18. Microenvironment-Driven Dynamic Heterogeneity and Phenotypic Plasticity as a Mechanism of Melanoma Therapy Resistance.
Ahmed F; Haass NK
Front Oncol; 2018; 8():173. PubMed ID: 29881716
[TBL] [Abstract][Full Text] [Related]
19. The traditional chinese medicine monomer Ailanthone improves the therapeutic efficacy of anti-PD-L1 in melanoma cells by targeting c-Jun.
Yu P; Wei H; Li K; Zhu S; Li J; Chen C; Zhang D; Li Y; Zhu L; Yi X; Liu N; Liu P; Zhao S; Chen X; Peng C
J Exp Clin Cancer Res; 2022 Dec; 41(1):346. PubMed ID: 36522774
[TBL] [Abstract][Full Text] [Related]
20. ZEB1 transcription factor promotes immune escape in melanoma.
Plaschka M; Benboubker V; Grimont M; Berthet J; Tonon L; Lopez J; Le-Bouar M; Balme B; Tondeur G; de la Fouchardière A; Larue L; Puisieux A; Grinberg-Bleyer Y; Bendriss-Vermare N; Dubois B; Caux C; Dalle S; Caramel J
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
